Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
Ninety patients with poorly differentiated prostatic carcinoma have been treated with Estramustine phosphate (Estracyt). Seventeen of them had clinically metastases and had had no previous therapy. Seventy-three were initially given oestrogens and/or irradiation. Objective response was observed in 59%. The best effect was seen in patients primarily untreated.
D000135:Acid Phosphatase / Q000097:blood; D001859:Bone Neoplasms / Q000556:secondary; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology
D009588:Nitrogen Mustard Compounds; D004961:Estramustine; D000135:Acid Phosphatase